RGRX Company Description
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration.
The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue.
It has strategic partnerships with Lee’s Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000.
RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
| Country | United States |
| Founded | 1982 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | J. Finkelstein |
Contact Details
Address: 15245 Shady Grove Road Rockville, Delaware 20850 United States | |
| Phone | 301 208 9191 |
| Website | regenerx.com |
Stock Details
| Ticker Symbol | RGRX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US75886X1081 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| J. J. Finkelstein | President, Chief Executive Officer and Director |
| Dr. Allan L. Goldstein Ph.D. | Founder, Chairman, Chief Scientific Officer and Chairman of Scientific Advisor Board |